PC786 shows effective antiviral activity against RSV-A (IC50 <0.09 to 0.71 nM) and RSV-B (IC50, 1.3 to 50.6 nM). PC786 is an inhaled respiratory syncytial virus L protein polymerase inhibitor.

RSV A:0.09-0.71 nM, RSV B:1.3-50.6 nM

PC786 shows effective inhibition of cytopathic effect (CPE) induced by known RSV A clinical isolates (IC50, 0.14 to 3.2 nM). PC786 also exhibits potent inhibition of CPE induced by various low-passage-number clinical isolates of RSV A (IC50, 0.42 nM [median]) and RSV B (IC50, 17.5 nM [median]). PC786 inhibits RSV A2 activity, exhibiting an IC50 and IC90 of 0.50±0.0014 nM and 0.63±0.035 nM, respectively. PC786 inhibits RSV B WST activity, exhibiting an IC50 and IC90 of 27.3±0.77 nM and 57.1±3.87 nM, respectively [1].

Treatment with PC786 (either intratracheal or intranasal; Once-daily on days-1 to 3), is found to inhibit viral loads in the lungs of RSV A2-infected BALB/c mice. The viral load is below the level of detection when the drug is given at 2 mg/mL (40 μg/mouse [approximately 1.6 mg/kg of body weight] for i.t. treatment, or 80 μg/mouse [approximately 3.2 mg/kg] for i.n. treatment)[1].